- The Clinical Genome Resource (ClinGen) is an international initiative that develops and applies evidence-based methods for understanding the relationships between human genes, genetic variants, and diseases. It provides curated information to support clinical genomics, rare disease diagnosis, precision medicine, and genetic research. One of its most important activities is gene–disease validity curation, which evaluates whether changes in a particular gene are genuinely associated with a specific disease. This is essential because identifying a rare variant in a gene does not automatically establish that the gene causes the patient’s condition.
- Gene–disease validity refers to the strength of the scientific evidence supporting or refuting a relationship between a gene and a particular disease. It is different from variant pathogenicity. Gene–disease validity asks whether variation in a gene can cause a disease, whereas variant classification asks whether a particular genetic change contributes to that disease. A gene may have a well-established relationship with a disorder, but an individual variant within that gene may be benign, uncertain, or pathogenic. Conversely, a rare variant in a gene with an uncertain disease relationship should not be assumed to explain a patient’s clinical presentation.
- ClinGen evaluates gene–disease relationships using a structured framework developed by its Gene Curation Working Group. The process considers genetic evidence, experimental evidence, and evidence that may contradict the proposed relationship. Genetic evidence can include observations of affected individuals carrying relevant variants, segregation of variants with disease in families, de novo occurrences, case-control data, and evidence from linkage studies. Experimental evidence may include studies of gene expression, protein function, cellular models, animal models, and other investigations that support a plausible disease mechanism. Evidence is assessed and scored systematically, with expert review used to reach a final classification.
- The ClinGen framework commonly classifies gene–disease relationships as definitive, strong, moderate, limited, or no known disease relationship. A definitive relationship is supported by substantial and repeatedly demonstrated evidence, including independent genetic observations over time, with no convincing contradictory evidence. A strong relationship has substantial supporting evidence but does not meet all requirements for the definitive category. A moderate relationship has meaningful evidence supporting causality, although additional independent observations or experimental support may be needed. A limited relationship is plausible but supported by insufficient evidence for a higher classification. No known disease relationship indicates that a qualifying causal relationship has not been established through the available evidence; it does not necessarily prove that the gene can never be associated with disease. Some curated relationships may also be identified as disputed or refuted when evidence challenges or contradicts the proposed association.
- An important part of gene curation is defining the disease being evaluated. A single gene may be associated with several disorders, and similar clinical features may occur in different genetic conditions. ClinGen therefore uses disease lumping and splitting principles to decide whether related clinical presentations should be considered one disease entity or separate conditions. Disease definitions and identifiers are important because gene–disease validity depends on the specific condition and inheritance model being assessed. The use of standardized disease ontologies, including MONDO, helps curators represent disease entities consistently and distinguish closely related disorders.
- Mode of inheritance is another central component of gene–disease curation. A gene may cause disease through autosomal dominant, autosomal recessive, X-linked, mitochondrial, or other inheritance mechanisms. Different modes of inheritance may involve different molecular mechanisms and require separate evaluations. For example, loss-of-function variants may cause a recessive disorder when both gene copies are affected, while a dominant disorder involving the same gene may result from haploinsufficiency, a dominant-negative effect, or a gain-of-function mechanism. Gene–disease validity should therefore be interpreted in relation to the relevant inheritance pattern rather than assuming that every variant in a disease-associated gene acts in the same way.
- ClinGen organizes specialist groups known as Gene Curation Expert Panels (GCEPs), which evaluate gene–disease relationships in particular disease areas. These panels bring together clinical geneticists, molecular biologists, genetic counsellors, laboratory specialists, and other experts. They apply standardized criteria while considering disease-specific knowledge and the available scientific literature. Expert-panel curation is particularly valuable in complex areas where the interpretation of genetic and experimental evidence requires specialized knowledge.
- ClinGen also develops resources for evaluating the pathogenicity of individual variants. Its Variant Curation Expert Panels (VCEPs) establish disease- or gene-specific recommendations for applying the American College of Medical Genetics and Genomics and Association for Molecular Pathology (ACMG/AMP) variant classification framework. These specifications help laboratories interpret evidence consistently for particular disorders. ClinGen’s work therefore connects gene-level validity assessment with the evaluation of individual variants, although the two processes answer different questions.
- The Gene Curation Interface (GCI) supports the structured collection, scoring, and documentation of evidence used in gene–disease validity assessments. Curators record relevant publications, genetic observations, experimental findings, inheritance information, and evidence scores. The resulting classifications and evidence summaries are made available through ClinGen’s public resources. The Variant Curation Interface (VCI) supports structured evaluation of evidence for individual genetic variants. These tools promote transparency and consistency by documenting how evidence contributes to a classification rather than presenting only a final label.
- The Gene Curation Expert Panel framework is complemented by the Gene–Disease Validity Standard Operating Procedures (SOPs), which describe the recommended curation workflow. The process includes defining the gene–disease relationship and inheritance model, gathering relevant publications, identifying and scoring genetic and experimental evidence, considering contradictory findings, and obtaining expert review and approval. The procedures are periodically updated as methods and scientific understanding develop. Researchers should consult the current SOP and associated training materials when performing or interpreting a formal ClinGen curation.
- The Gene Curation Working Group also addresses the quality and consistency of evidence summaries. A useful evidence summary should explain why a gene is considered related to a disease, describe the principal supporting findings, identify limitations or contradictory evidence, and make the classification understandable to readers. This is important because a validity category alone cannot communicate every detail of the evidence. Two gene–disease pairs with the same classification may have different underlying evidence, disease mechanisms, and levels of clinical relevance.
- The Gene Curation Expert Panel results are useful for prioritizing candidate genes during rare disease analysis. When a patient’s sequencing data reveal several rare variants, a gene with a definitive or strong relationship to a compatible disorder may deserve closer investigation than a gene with only limited evidence. However, gene validity should not be used as the sole prioritization criterion. The patient’s phenotype, inheritance pattern, variant consequence, population frequency, segregation data, and molecular mechanism must also be considered. A highly ranked candidate gene does not automatically contain the causal variant.
- Several other resources complement ClinGen in the evaluation of gene–disease relationships. The Gene Curation Coalition (GenCC) brings together information from multiple organizations that evaluate gene–disease associations. It provides a consolidated view of gene–disease validity assertions from participating sources, helping researchers compare classifications and identify differences in evaluation. Because contributing organizations may use different methods and evidence thresholds, users should examine the source and criteria behind each assertion rather than assuming that all classifications are directly equivalent.
- OMIM, the Online Mendelian Inheritance in Man database, is a major resource for human genes and inherited disorders. It provides detailed descriptions of disease phenotypes, inheritance patterns, gene associations, and important discoveries in human genetics. OMIM is widely used in rare disease research and clinical genetics, but its disease descriptions and gene associations should be distinguished from formal ClinGen gene–disease validity classifications. OMIM is particularly useful for understanding the historical and clinical context of a genetic disorder.
- Orphanet is an international resource focused on rare diseases and orphan drugs. It provides information about rare disease definitions, clinical characteristics, epidemiology, inheritance, diagnostic resources, and disease classification. Its standardized disease identifiers and nomenclature support communication between researchers and healthcare professionals. Orphanet can be used alongside ClinGen and OMIM to investigate rare disorders and clarify the clinical conditions associated with candidate genes.
- PanelApp, developed within the Genomics England programme, provides expert-reviewed gene panels for particular diseases and clinical indications. Genes are assigned evidence-based confidence ratings, commonly represented by green, amber, and red categories. Green genes have stronger evidence supporting their inclusion in a panel, amber genes have more limited or emerging evidence, and red genes have insufficient evidence or are not recommended for routine diagnostic use within that panel. PanelApp is especially useful for designing and evaluating diagnostic gene panels, although its ratings should not be treated as identical to ClinGen’s gene–disease validity classifications.
- Gene2Phenotype is another resource that links genes with disease-associated phenotypes and inheritance information. It supports phenotype-driven analysis by providing gene–disease relationships and associated clinical features. The Developmental Disorders Genotype–Phenotype Database (DDG2P), associated with rare developmental disorders research, has also been used to support the prioritization of candidate genes in diagnostic investigations. These resources are useful when analysing patients with developmental delay, intellectual disability, congenital anomalies, and other complex phenotypes.
- DECIPHER provides genomic and phenotypic information relevant to rare disease diagnosis, including data on copy-number variants, sequence variants, and genotype–phenotype relationships. It supports the investigation of genomic regions and candidate genes associated with developmental and other genetic disorders. Because some DECIPHER information involves patient-level genomic and clinical data, access and data use may be subject to consent and governance requirements. Its clinical and research resources can complement ClinGen, OMIM, and phenotype ontologies.
- The Human Phenotype Ontology (HPO) is particularly important for connecting clinical observations with gene–disease knowledge. It provides standardized terms for describing features such as seizures, developmental delay, hearing loss, skeletal abnormalities, and cardiac defects. Phenotype terms can be used to compare a patient’s clinical presentation with disease-associated features in resources such as OMIM, Orphanet, and gene–phenotype databases. Tools including Exomiser and Phen2Gene use phenotype similarity and genetic information to help prioritize candidate genes. Phenotype matching is a prioritization method, however, and does not independently establish a diagnosis or prove a gene–disease relationship.
- Gene–disease validity resources are also important for evaluating newly proposed disease genes. In research studies, a gene may be associated with a disorder based on one or a small number of affected individuals. Such observations can provide valuable initial evidence, but additional unrelated cases, segregation data, functional studies, and independent replication may be needed to establish a reliable relationship. Researchers should distinguish between a candidate gene, a reported gene–disease association, and a relationship supported by systematic expert curation.
- Contradictory evidence is an important part of gene curation. A proposed relationship may be challenged when later studies fail to replicate earlier findings, when variants do not segregate with the disease, when functional experiments do not support the proposed mechanism, or when the original clinical observations are reassessed. Negative evidence should be evaluated carefully because differences in phenotype, penetrance, variant type, experimental design, and study power can affect the interpretation. Transparent documentation of both supportive and contradictory findings helps prevent weak associations from becoming established clinical assumptions.
- Gene–disease validity is not permanent. New families, improved sequencing technologies, functional studies, and revised disease definitions can change the strength of evidence over time. ClinGen and other curation initiatives therefore support re-evaluation of previously assessed relationships. Version tracking and the date of a classification are important when using these resources in clinical pipelines, research publications, and diagnostic reports. A classification retrieved today may differ from an earlier assessment because the evidence base or curation framework has changed.
- In bioinformatics, ClinGen and related gene–disease validity resources provide an essential bridge between genomic data and established medical knowledge. They help researchers distinguish well-supported disease genes from emerging candidates, prioritize variants in diagnostic workflows, evaluate the reliability of genetic associations, and improve the interpretation of rare disorders. Their greatest value comes from combining curated gene–disease evidence with variant-level classification, population frequencies, phenotype information, inheritance patterns, and functional data. Together, these resources support more transparent, reproducible, and evidence-based genomic research and clinical interpretation.